Synergistic anticancer activity of 1,25-dihydroxyvitamin D-3 and immune cytokines: the involvement of reactive oxygen species

Citation
R. Koren et al., Synergistic anticancer activity of 1,25-dihydroxyvitamin D-3 and immune cytokines: the involvement of reactive oxygen species, J STEROID B, 73(3-4), 2000, pp. 105-112
Citations number
50
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
ISSN journal
09600760 → ACNP
Volume
73
Issue
3-4
Year of publication
2000
Pages
105 - 112
Database
ISI
SICI code
0960-0760(200006)73:3-4<105:SAAO1D>2.0.ZU;2-W
Abstract
It was previously shown that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) enh ances the cytotoxic activity of tumor necrosis factor alpha (TNF alpha), do xorubicin and menadione. A feature shared by these anticancer agents is the involvement of reactive oxygen species (ROS) in their action. In this work we found that 1,25(OH)(2)D-3 acted synergistically with interleukin 1 beta (IL-1 beta) or interleukin 6 (IL-6) to inhibit the proliferation of MCF-7 breast cancer cells. The extent of the synergism was maximal at 1 nM, a con centration at which 1,25(OH)(2)D-3, acting singly, only marginally reduced the cell number. The thiol antioxidant, N-acetylcysteine (NAC) abolished th e synergism between IL-1 beta or IL-6 and 1,25(OH)(2)D-3, but had only a sm all protective effect when the cytokines acted alone. NAC and reduced gluta thione (GSH) protected MCF-7 cells from cytotoxicity induced both by TNF al pha alone and by TNF alpha and 1,25(OH)(2)D-3. A two-day exposure to TNF al pha caused a 27.7 +/- 3.1% (mean +/- SEM) reduction in GSH content. This ef fect increased to 46.4 +/- 5.5% by co-treatment with 1,25(OH)(2)D-3 which d id not affect GSH levels on it own. We conclude that 1,25(OH)(2)D-3 can act synergistically with anticancer cytokines present in the tumor milieu and that ROS plays a mediatory role in this interaction. (C) 2000 Elsevier Scie nce Ltd. All rights reserved.